Angelman Syndrome (AS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Angelman Syndrome Disorder Marketed and Pipeline Drugs Report Overview
Angelman Syndrome (AS) is a genetic condition that affects the nervous system and causes severe physical disabilities, learning disabilities, motor dysfunction, seizure disorder, and often a happy, sociable disposition. A person with AS will have a near-normal life expectancy, but they will need support throughout their life. Some delayed development can be observed at ages 6–12 months, while other common symptoms usually occur before age three years.
The Angelman Syndrome marketed and pipeline drugs market research report includes an assessment of the disease epidemiology, leading marketed products with sales forecast, pricing, and reimbursement, late-to-mid-stage pipeline products with phase transition success rate (PTSR), and the likelihood of approval (LoA) for Angelman Syndrome.
Angelman Syndrome Pipeline Drugs Segmentation by Mechanisms of Action
The key mechanisms of action for AS pipeline drugs are enzyme activator, enzyme inhibitor, receptor agonist, receptor antagonist, and ion channel activator. Most of the AS pipeline drugs are enzyme activators.
Angelman Syndrome Pipeline Drugs Analysis by MoA, 2023 (%)
For more MoA insights into the Angelman Syndrome pipeline drugs market, download a free report sample
Angelman Syndrome Pipeline Drugs Segmentation by Routes of Administration
The key routes of administration for AS pipeline drugs are oral and injection. The pipeline drugs for AS include oral therapies and injectables in equal proportion.
Angelman Syndrome Pipeline Drugs Segmentation by Molecule Type
Most of the pipeline drugs for AS are biologics. Small molecules and oligonucleotides are the other significant molecule types in the pipeline drugs for Angelman Syndrome.
Angelman Syndrome Pipeline Drugs Analysis by Molecule Types, 2023 (%)
For more molecule type insights into the Angelman Syndrome pipeline drugs market, download a free report sample
Top Sponsors in the Angelman Syndrome Marketed and Pipeline Drugs Market
Some of the top sponsors in the Angelman Syndrome marketed and pipeline drugs market are Ovid Therapeutics Inc, Neuren Pharmaceuticals Ltd, F.Hoffmann-La Roche Ltd, Radius Health Inc, Children’s Research Institute, Proveca Ltd, and Ionis Pharmaceuticals Inc. Commercial sponsors dominated the clinical trials space in AS over the past 10 years, with Ovid Therapeutics sponsoring the highest number of clinical trials overall.
Angelman Syndrome Pipeline Drugs Market Report Overview
Key Mechanisms of Action | Enzyme Activator, Enzyme Inhibitor, Receptor Agonist, Receptor Antagonist, and Ion Channel Activator |
Key Routes of Administration | Oral and Injection |
Key Molecule Types | Small Molecule, Biologic, and Oligonucleotide |
Top Sponsors (Marketed and Pipeline Drugs) | Ovid Therapeutics Inc, Neuren Pharmaceuticals Ltd, F.Hoffmann-La Roche Ltd, Radius Health Inc, Children’s Research Institute, Proveca Ltd, and Ionis Pharmaceuticals Inc |
Segments Covered in the Report
Angelman Syndrome Pipeline Drugs Mechanisms of Action Outlook (Number of Drugs, 2023)
- Enzyme Activator
- Enzyme Inhibitor
- Receptor Agonist
- Receptor Antagonist
- Ion Channel Activator
Angelman Syndrome Pipeline Drugs Routes of Administration Outlook (Number of Drugs, 2023)
- Oral
- Injection
Angelman Syndrome Pipeline Drugs Molecule Types Outlook (Number of Drugs, 2023)
- Small Molecule
- Biologic
- Oligonucleotide
Scope
GlobalData’s Angelman Syndrome: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Annual Therapy Cost
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the AS market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global AS market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
Frequently asked questions
-
What are the key mechanisms of action for AS pipeline drugs?
The key mechanisms of action for AS pipeline drugs are enzyme activator, enzyme inhibitor, receptor agonist, receptor antagonist, and ion channel activator.
-
What are the key routes of administration for AS pipeline drugs?
The key routes of administration for AS pipeline drugs are oral and injection.
-
What are the key molecule types for AS pipeline drugs?
The key molecule types in the AS pipeline drugs market are small molecule, biologic, and oligonucleotide.
-
Who are the top sponsors for Angelman Syndrome marketed and pipeline drugs market?
Some of the top sponsors for the Angelman Syndrome marketed and pipeline drugs market are Ovid Therapeutics Inc, Neuren Pharmaceuticals Ltd, F.Hoffmann-La Roche Ltd, Radius Health Inc, Children’s Research Institute, Proveca Ltd, and Ionis Pharmaceuticals Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.